Biopôle Clermont-Limagne
Technology park for life sciences
Year of creation : 2017
Statut : simplified joint stock company
Size : 7
% of CA dedicated to R&D : 100
Patents (number of) : 0

Contact details

Biopôle Clermont-Limagne

5 rue Emile Duclaux

63360 Saint-Beauzire



Contact : Thierry BERNARDI
Phone : +33 473 333 980
Email : contact@biofilmpharma.fr
Website : www.biofilmpharma.fr

BioFilm Pharma

The next generation of AntiMicrobials will be AntiBiofilms


With its activity of discovering very innovative antimicrobial active ingredients, BioFilm Pharma targets Chronic Infections, caused by the persistence of biofilm.

As a priority, the company targets among Chronic Wounds the main indication affecting the diabetic population: the foot ulcer (15 million new cases each year), which represents a huge additional cost for the health system in high-income countries (4 billion euros). BioFilm Pharma exclusively operates a unique patented technology, and develops "antibiofilm" products to prevent and cure chronic bacterial infections. The company has already identified 15 nuggets, 2 are engaged in a Lead Optimization process, these are potential blockbusters close to proof of concept on patients.